Seminar: Automated & Scalable Cell & Gene Therapy Manufacturing Strategies

Discover cutting-edge technologies, network with industry experts, and gain valuable insights into the future of this rapidly advancing field. These therapies have the potential to revolutionise medical treatments by delivering gene payloads to correct genetic disorders or produce genetically-modified cell-based therapies for oncology and autoimmune indications. Don't miss this opportunity to stay ahead of the curve and revolutionise the world of healthcare. Register now to secure your spot. The online teams invite will be shared with registered attendees ahead of the meeting.
 
The seminar will focus on the bioprocessing and manufacturing considerations of CGT products and will introduce the work producing stem cells and CAR-T cells in bioreactors at the litre-scale. The talk will also focus on the development of relevant small-scale models as well as automated, robotic manufacturing platforms for the large-scale production of gene-modified cellular therapies. In particular, this talk will cover the development of standardised, scalable and robust manufacturing processes for the consistent manufacture of clinical-grade CGTs, strategies for identifying and minimising variability associated with input material for cell therapy manufacture, development of suitable manufacturing scale-down models and Quality by Design approach to improve final product quality.

Chaired by: Dan Bracewell, Professor of Bioprocess Analysis at the UCL Department of Biochemical Engineering

The UCL-Pall/Cytiva Centre of Excellence (CoE) is a strategic industrial research initiative setup in 2018 to foster innovation, facilitate knowledge transfer, and address critical bioprocessing industrial challenges. With support from EPSRC & MRC Prosperity Partnership fund the Centre will now continue until 2029 with a focus on "Smart Biomanufacturing for Genomic Medicines," to address the challenges of manufacturing revolutionary genomic medicines. The partnership will improve patient access to these transformative therapies and establish manufacturing innovation in a high-growth sector that will result in societal and economic impact.